Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CHAT | P28329 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10701359 | 1.00 | NFE2L2 (0.48) | NFE2L2MAOBCYP19A1MAOATRPA1 | |
| SCHEMBL27512901 | 0.87 | MAOB (0.56) | NFE2L2MAOBCYP19A1MAOAGRM4 | |
| SCHEMBL478037 | 0.85 | NFE2L2 (0.58) | NFE2L2MAOBCYP19A1MAOATRPA1 | |
| SCHEMBL478036 | 0.85 | NFE2L2 (0.58) | NFE2L2MAOBCYP19A1MAOATRPA1 | |
| SCHEMBL5431188 | 0.83 | MAOB (0.56) | NFE2L2MAOBCYP19A1MAOATRPA1 | |
| SCHEMBL911942 | 0.83 | MAOB (0.56) | NFE2L2MAOBCYP19A1MAOATRPA1 | |
| SCHEMBL3885086 | 0.83 | MAOB (0.56) | NFE2L2MAOBCYP19A1MAOATRPA1 | |
| (Z)-1,2-Diphenylethene SCHEMBL28164872 | 0.83 | MAOB (0.56) | NFE2L2MAOBCYP19A1MAOATRPA1 | |
| SCHEMBL29397541 | 0.83 | MAOB (0.56) | NFE2L2MAOBCYP19A1MAOATRPA1 | |
| SCHEMBL11086932 | 0.83 | NFE2L2 (0.41) | NFE2L2MAOBCYP19A1MAOATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6991858-B2 | Blue light-emitting compound for organic electroluminescent device and organic electroluminescent device using the same | SAMSUNG SDI CO., LTD. (KR) | 2006-01-31 | — | — | US | disclosed |
| US-20040001971-A1 | Blue light-emitting compound for organic electroluminescent device and organic electroluminescent device using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040001971-A1 | Blue light-emitting compound for organic electroluminescent device and organic electroluminescent device using the same | LEF1, ELP1, IK | NFE2L2 516/4885MAOB 1673/4885CYP19A1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.